Journal article
Genetic associations with brain microbleeds Systematic review and meta-analyses
SS Maxwell, CA Jackson, L Paternoster, C Cordonnier, V Thijs, R Al-Shahi Salman, CLM Sudlow
Neurology | Published : 2011
Abstract
Objective: We performed a systematic review and meta-analyses to assess the evidence for genetic associations with brain microbleeds (BMBs). Methods: We sought all published studies of the association between any genetic polymorphism and BMBs studied in a total of >100 people. We critically appraised studies, and calculated pooled odds ratios (ORs) using the generic inverse variance fixed effects method. We used I2 and × 2 statistics to assess heterogeneity, and fail-safe N estimates to assess the robustness of our results. Results: Only the APOE ξ2/3/4 polymorphism had been studied in >100 people (10 studies, 7,351 participants). Compared with people with the ξ3/ξ3 genotype, carriers of the..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
Supported by the Binks Trust, UK (C.A.J.), a MRC UK PhD studentship (L. P.), an MRC UK Clinician Scientist award (R.A.-S.S.), a Fundamental Clinical Research Grant from FWO Flanders (V. T.), and the Scottish Funding Council (C.L.M.S.).S.S. Maxwell has received funding for travel from the Centre for Clinical Brain Sciences and scholarship support from the Wellcome Trust. Dr. Jackson receives/has received research support from the MRC UK, the Binks Trust, and the Wellcome Trust. Dr. Paternoster has received support from an MRC PhD studentship. Dr. Cordonnier reports no disclosures. Prof. Thijs serves on scientific advisory boards for SYGNIS Pharma AG, MSD, Shire plc, and Boehringer Ingelheim; has received funding for travel from Shire plc and Boehringer Ingelheim; serves on speakers' bureaus for Shire plc, Abbott, Pfizer Inc., Boehringer Ingelheim, and Medtronic, Inc.; receives research support from Servier, Schering-Plough Corp., Sygnis Pharma AG, CoAxia, Inc., Medtronic, Inc., Novo Nordisk, Bristol-Myers Squibb, Pfizer Inc, Shire plc, AstraZeneca, ThromboGenics NV, Eli Lilly and Company, sanofi-aventis, Boehringer Ingelheim, Daii-chi Sankyo, Asubio Pharmaceuticals, Inc., FWO Flanders, and Vlaams Instituut voor Biotechnologie (VIB); and holds stock/stock options in Novo Nordisk. Dr. Al-Shahi Salman serves on the editorial board of Stroke and has received research support from the MRC UK, the UK Stroke Association, the Chief Scientist Office of the Scottish Government Health Department, and Chest Heart & Stroke Scotland. Dr. Sudlow serves on the editorial boards of Stroke and BioMed Central Cardiovascular Disorders; receives publishing royalties for Stroke: A Practical Guide to Management, 3rd ed. (Blackwell, 2008); and receives/has received research support from the Chief Scientist Office of the Scottish Executive Health Department, the Stroke Association, the Wellcome Trust, and the Binks Trust.